Litcius/Paper detail

Structural basis of Epstein-Barr virus gp350 receptor recognition and neutralization

Cong Sun, Xin‐Yan Fang, Guo‐Long Bu, Lan‐Yi Zhong, Chu Xie, Gexin Zhao, Sen‐Fang Sui, Zheng Liu, Mu‐Sheng Zeng

2025Cell Reports14 citationsDOIOpen Access PDF

Abstract

Epstein-Barr virus (EBV) is an oncogenic virus associated with multiple lymphoid malignancies and autoimmune diseases. During infection in B cells, EBV uses its major glycoprotein gp350 to recognize the host receptor CR2, initiating viral attachment, a process that has lacked direct structural evidence for decades. In this study, we resolved the structure of the gp350-CR2 complex, elucidated their key interactions, and determined the site-specific N-glycosylation map of gp350. Our findings reveal that CR2 primarily binds to gp350 through an electrostatically complementary and glycan-free interface and that the diversity of key residues in CR2 across different species influences EBV host selectivity mediated by gp350. With the confirmed binding, we constructed a CR2-Fc antibody analog that targets the vulnerable site of gp350, demonstrating a potent neutralization effect against EBV infection in B cells. Our work provides essential structural insights into the mechanism of EBV infection and host tropism, suggesting a potential antiviral agent.

Topics & Concepts

TropismVirologyBiologyVirusGlycanGlycosylationIntegrasesAntibodyGlycoproteinEpstein–Barr virusNeutralizationImmunologyGeneticsHuman immunodeficiency virus (HIV)IntegraseViral-associated cancers and disordersLymphoma Diagnosis and TreatmentCytomegalovirus and herpesvirus research